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SYNOPSIS
Previously published studies found a better survival for DCC than for  pancreatic ductal 
adenocarcinomas (PDAC), but those results were based on uncontrolled cohorts analyses. Our
work studied specifically prognosis of DCC, comparing it PDAC, by a propensity score. 
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ABSTRACT
Background : Prognosis of distal cholangiocarcinoma (DCC) after pancreaticoduodenectomy
(PD) remains poorly assessed. The aims of this study were to describe the oncological results
of PD in DCC and to compare its prognosis to pancreatic ductal adenocarcinoma (PDAC).
Methods: All PD for periampullary carcinoma performed between January 2000 and March
2013 were extracted from a prospective database. Risk factors likely to influence overall (OS)
and disease-free (DFS) survivals of DCC were assessed by multivariable analyses. The DCC
and  PDAC  prognoses  were  compared  after  matching  using  propensity  score  (nearest
neighbour matching). 
Results: Of the 290 patients analysed, 56 had DCC, with a mean age of 65 ± 15 years. The
median OS was 36.9 months. Recurrence occurred in 35 patients (67%), mostly in the liver
(37%). The median DFS was 14.6 months. Combined organ  resection was an independent
risk factor for worse OS and DFS (p= 0.01 and p = 0.001, respectively). Matching analysis
found no significant difference between DCC and PDAC in terms of OS (p=0.284) or DFS
(p=0.438). 
Conclusion: This first propensity analysis demonstrated that DCC and PDAC have the same
prognosis, linked to the high rate of early recurrence, particularly associated with the need for
combined organ resection. 
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INTRODUCTION
Distal cholangiocarcinoma (DCC) is an epithelial tumour developed from the lower third of
the extrahepatic bile duct and accounts for 30 to 40 percent of all cholangiocarcinomas  (1)
and 11 to 20% of all periampullary cancers  (2,3). The typical risk factors of DCC are male
gender, older age and chronic biliary inflammation (4). Two pre-cancerous lesions have been
identified:  intraepithelial  neoplasms  and  intraductal  and  papillary  tumours  (5).  The  only
potentially curative treatment for DCC is pancreaticoduodenectomy (PD), and chemotherapy
can achieve a partial response or stabilize the disease in patients who are unresectable (6,7). In
contrast  to  pancreatic  ductal  adenocarcinomas  (PDAC),  the  administration  of  adjuvant
chemotherapy following curative PD for DCC remains controversial and is currently under
debate. Even when surgery with curative intent is performed, the 5-year survival rate is only
approximately 30 to 40% (8,9,10). This is closely related to local recurrence and metastatic
spread. Therefore,  increased understanding of the risk factors of recurrence is essential  to
allow for the earliest possible diagnosis of DCC recurrence and for rapid implementation of
chemotherapy or local treatment of liver metastases, such as radiofrequency ablation (11). 
To  date,  few  studies  have  specifically  focused  on  studying  DCC  within  periampullary
tumours. Previously published studies found a better survival for DCC than for  PDAC, but
those results were based on uncontrolled cohorts analyses (12,13).
The aim of the present study was to examine the outcomes after PD for DCC with focus on
the risk factors influencing recurrence and survival. In addition, this study aimed to compare
differences in prognosis between patients with DCC and PDAC treated by curative PD based
on a matching analysis using a propensity score.
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MATERIALS AND METHODS
All consecutive patients who underwent PD for periampullary cancers in a tertiary referral
centre between January 2000 and April 2013 were extracted from a prospective maintained
database  and were analysed  retrospectively.  The diagnosis  of  periampullary  cancers  were
suspected on preoperative imaging data or biopsy, but only DCC and PDAC pathologically
confirmed on surgical specimens were included. Ampullary and duodenal carcinomas were
excluded  from the  analysis.  This  work  was  conducted  after  approval  by  the  institutional
review board.
The  data  collected  included  demographics  (age,  sex,  body mass  index  (BMI),  American
Society of Anaesthesiologists (ASA) score (14)), tumour type, lymph node status, duration of
surgery, venous or arterial resection and reconstruction, concomitant abdominal surgery, and
transfusion  requirement. Postoperative pancreatic fistulas were included in the analysis and
were classified  according to  the  International  Study Group of  Pancreatic  Fistula  (ISGPF)
classification  (15).  Incidences  of  delayed  gastric  emptying  (DGE)  were  included  in  the
analysis and were classified according to the International Study Group of Pancreatic Surgery
classification  (ISGPS)  (16).  In this  study,  only DGE of  grades  B and C were considered
because the nasogastric tube was systematically left in place until postoperative day 5. Post-
pancreatectomy haemorrhage,  including intra-  and extraluminal  bleeding  according  to  the
ISGPS definition; biliary fistula, defined as the presence of bile in the drainage fluid; and
systemic infections, defined as the presence of infectious signs requiring the administration of
systemic antibiotics, were also assessed. Perioperative mortality was defined as death during
the  initial  hospital  stay  or  by  POD  30  or,  if  the  patient  was  discharged,  by  POD  90.




All PD were performed following the standard Whipple procedure and Child reconstruction
by senior pancreatic surgeons. An initial superior mesenteric artery approach was performed
systematically after 2006. All PD in periampullary carcinoma were standardized, including
the same lymph node dissection. All patients had intraoperative frozen section examination of
the proximal main bile duct and the pancreatic section of the specimen. If invaded, additional
resection to achieve a negative margin was performed. During reconstruction, pancreatic duct
intubation was left to the discretion of the operator, but was generally performed in cases with
small  duct  size  (<3  mm)  or  soft  pancreatic  texture.  Since  2005,  a  nasojejunal  tube  was
systematically placed during surgery at 30 cm downstream from the gastrojejunostomy in the
efferent jejunal limb for the administration of postoperative enteral nutrition.
Pathology
The histological diagnosis was established by an expert pathologist in bilio-pancreatic disease
according  to  the  macroscopic  and  microscopic  aspect and  immunohistochemistry  (with
cytokeratin  7  and  20).   When  distinction  between  DCC  and  PDAC  was  questionable,
specimen was reviewed by a second pathologist who confirmed the diagnosis. Considering
the  microscopic  margin  involvement,  pathologists  used  a  definition  based  on  a  1  mm
clearance, to specify R0 resection.
Follow-up protocol
After resection, all patients were followed every 3 months. A computed tomography scan was
systematically performed every 3 months during the first 2 years after surgery and every 6
months thereafter.  Follow-up data were obtained through routine clinical visits  or through
personal contact. The end of follow-up was between 1 February 2014 and 1 April 2014 or was
at the time of death.
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Recurrence
Recurrence  was  considered  when  new  lesion  was  shown  on  imaging  finding  without
histological  confirmation.  When  recurrence  was  diagnosed,  the  treatment  strategy  was
determined at a multidisciplinary collaborative meeting,  which was attended by pancreatic
surgeons,  radiologists,  oncologists  and  gastroenterologists.  According  to  their  general
condition and the degree of disease extension, the patients were treated with chemotherapy,
radiation  therapy  or  radiofrequency  ablation.  Patients  with  general  recurrence  received
systematic chemotherapy, using gemcitabine or gemcitabine plus oxaliplatin (GEMOX). For
localized  non-progressive  liver  metastases,  the  feasibility  of  radiofrequency  ablation  and
surgical resection were systematically discussed. 
Statistical analysis
Quantitative variables are expressed as the means ± standard deviation (SD) or as medians
and ranges and were compared using Student’s t-test  or the Wilcoxon test as appropriate.
Qualitative variables are expressed as numbers and percentages and were compared using the
Chi-squared  or  Fisher’s  exact  test,  as  appropriate.  Survival  analysis  was  performed  by
Kaplan-Meier curve analysis (all patients were included in survival analysis, even those who
died postoperatively),  and the results were compared with the log-rank test.   All variables
with  p<0.10  by  univariate  analysis  were  entered  into  a  multivariate  model  (i.e.,  COX
proportional hazard model). The best final multivariate model was selected using a stepwise
method in order to only retain variables with a p value of <0.05.
The  propensity  score  was  calculated  for  each  patient  and  included  variables  known  to
significant  influence  outcomes  (i.e.,  age,  gender,  BMI,  T  stage,  N  stage,  microvascular
invasion,  perineural  infiltration,  necessity  of  vascular  resection,  and  R0  resection
achievement). Patients with DCC were matched to the closest patient with PDAC at a 1:1
ratio and then compared using the log-rank test.
A p  value  of  < 0.05 was considered  statistically  significant.  All  statistical  analyses  were
performed using R statistical software, version 2.15.1 (http://www.r-project.org/).
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RESULTS
Demographic and operative data
During the study period, 290 patients underwent PD with curative intent for periampullary
tumours, including 56 patients (19.3%) treated for DCC (32 men, 24 women) and 182 patients
(63%) for PDAC  (Figure 1). For the patients with DCC, the mean age at surgery was 65
years  (±  15.1 range:  40 -  86).  Before  surgery,  endoscopic  stenting  was performed  in 18
patients (32.1%). The preoperative dilatation rate of the pancreatic duct was 28.6%. None of
the patients underwent preoperative chemotherapy.
The mean operative time was 327 min (± 183 range: 170 - 590) (Table 3). The adjacent organ
resection (colon, liver or liver and colon combination) and vascular resection were required
for 8.9% and 16.1% of patients, respectively, for R0 resection. Patients requiring resections of
adjacent organs had no postoperative complications related to this resection.
 All patients had tumor free proximal bile duct margin, after frozen section analysis. Drainage
of the pancreatic duct was performed in 36 patients (64.3%). 
The pathological findings showed that complete tumour removal (RO resection) was achieved
in 49 patients (87.5%). Lymph node metastasis  was found in 28 patients (50%). Vascular
invasion  was  present  in  16  patients  (28.6%),  and  perineural  invasion  was  present  in  23
patients (41.1%). 
The postoperative complications included pancreatic fistula in 7 patients (12.5%), abdominal
infection in 11 patients (19.6%), bleeding in 13 patients (23.2%). Reoperation was necessary
in 12 patients (21.4%); 11 (92%) was linked either to a hematoma, or an active bleeding, one
(8%) reoperation was required to an isolated pancreatic fistula. The perioperative mortality
was  7.1%  at  30  days  after  the  operation  and  12.5%  at  90  days  after  the  operation.
Postoperative  chemotherapy  was  administered  to  14  patients  with  DCC (25%),  while  36
patients with PDAC (64%) received adjuvant chemotherapy. 
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Survival and recurrence rates
The mean Follow-up was 28.8 months. The overall median survival (OS) was 36.9 months,
with actuarial survival rates at 1, 3 and 5 years of 74.5%, 31.8%, and 27.1%, respectively. The
median disease-free survival (DFS) was 14.6 months, with actuarial survival rates at 1, 3 and
5 years of 57.1%, 31.8% and 19.7%, respectively. 
Recurrence occurred in 35 of the 52 patients (67%) who were still alive after the postoperative
period, with an mean delay of 13 months. The most frequent form of recurrence was isolated
liver  metastasis  (n=13,  37%),  followed  by  local  recurrences  (n=9,  26%),  peritoneal
carcinomatosis (n=7, 20%), and lung metastasis (n=4, 11%), and others locations (n=2, 6%).
Details  of  recurrence  are  summarized  in  Figure  2.  The  treatments  for  recurrence  were
chemotherapy for 28 patients (80%), chemotherapy combined with radiofrequency ablation
for one patient (2.9%), radiofrequency ablation for one patient (2.9%) and radiotherapy for
one patient (2.9%). 
Factors influencing OS
Of the 19 variables assessed by univariable analysis, need for organ resection (p = 0.032), R1
resection  (p  =  0.003),  tumour  size  >  2  cm  (p  =  0.047),  vascular  invasion  (p  =  0.05),
occurrence of postoperative haemorrhage (p = 0.032) were significantly associated with a
worse overall survival. On multivariate analysis, only need for organ resection (HR 4.31 [1.38
-  13.42],  p  = 0.012),  R1 resection  (HR 4.37 [1.63 -  11.7],  p  = 0.003)  and postoperative
haemorrhage (HR 1.45 [1.73 - 10.47], p = 0.002) remained significant independent factors
influencing overall survival (Table 1).
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Risk factors for recurrence
The univariable analyses showed that male gender (p = 0.039), need for organ resection (p =
0.001), R1 resection (p = 0.014), tumour size > 2 cm (p = 0.05), vascular invasion (p = 0.012),
postoperative abdominal infection (p = 0.034), and occurrence of biliary fistula (p = 0.013),
were significantly related to DFS.
For the multivariable analysis, only male gender (HR= 3.29 [1.6 - 6.78], p = 0.001), need for
organ resection (HR= 7.1 [2.17 - 23.23], p = 0.001), vascular invasion (HR= 2.71 [1.41 - 5.2])
p  =  0.003),  and  abdominal  infection  after  surgery  (HR=  3.39  [1.46  -  7.88]  p  =  0.004)
remained significant independent factors related to DFS (Table 2). 
Comparison of prognosis for DCC and PDAC 
The  characteristics  (e.g.,  demographic  and  perioperative  data,  pathological  findings  and
postoperative outcomes) of the two matched groups are reported in table 3. The propensity
score matching (1:1) of patients who underwent PD for DCC and PDAC did not find any
significant  differences  in  OS (p=0.284)  or  DFS (p  =  0.438)  (Figure  3).  When excluding
patients who died in postoperative period (n=4, 7.1%), DCC and PDAC still have similar
outcomes  (Supplementary files, Figure 1). 
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DISCUSSION
DCC is a tumour associated with poor prognosis due to the high rate of recurrence despite the
performance of PD with curative intent. Few studies have specifically focused on oncological
outcomes of resected DCC, and, in particular,  few studies have tried to determine factors
associated with recurrence.  The present study focused on 56 patients who underwent PD for
DCC with curative intent and provides two important sets of data. The first set of data showed
that recurrence occurred frequently (67%), precociously (13 months on average), and usually
in  the  liver  (37%).  The  second  set  of  data  provided  novel  and  important  information
concerning the true prognosis of resected DCC compared to that of resected PDAC. For the
first time, the present analysis demonstrated that OS and DFS of resected DCC were similar
to those of resected PDAC using a relevant method of matching based on a propensity score
(p=0.284, p=0.43, respectively).
Although  PD  is  performed  with  curative  intent,  long-term  overall  and  recurrence  free
survivals remain disappointing, and a better understanding of recurrence and its risk factors is
necessary to identify high-risk individuals. To date, the independent factors that have been
shown to likely be associated with the prognosis of DCC are vascular and perineural invasion,
the status of the surgical margin and lymph node involvement  (9,18,19).  In particular, the
number of involved lymph nodes and its  ratio  (LNR) seems to be highly correlated  with
survival of resected DCC (2,20–22). However, it is difficult to clearly identify a relevant cut-
off value for the total number of involved lymph nodes because that number has not been
comparable  between  different  studies,  and previous  studies  have  had small  sample  sizes.
While it is widely accepted that a examining a greater number of lymph nodes allows for
more accurate staging, the number of involved nodes is not applied in the current American
Joint  Committee  on  Cancer  (AJCC)  TNM  classification  system  for  DCC,  unlike  in  the
classification systems for gastric and colorectal cancer. 
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In the same regard, the current study systematically performed lymph node dissection and
found that one half of patients had positive lymph node status, but the results did not confirm
any impact of lymph node involvement on OS (p=0.38) or DFS (0.88). Similarly, Noji et al.
demonstrated  that  extracapsular  lymph  node  involvement  had  no  impact  on  the  survival
(p=0.418) of DCC after resection with curative intent (23).  The results of the present study
support several other independent risk factors associated with poor DFS: i) male gender (HR=
3.29 [1.6 - 6.78], p= 0.001); ii) need for organ resection (HR= 7.1 [2.17 - 23.23], p= 0.001);
iii) vascular  invasion  (HR=  2.71  [1.41  -  5.2])  p=  0.003);  and  iv)  abdominal  infection
following surgery (HR= 3.39 [1.46 - 7.88] p= 0.004). These independent risk factors should
allow for accurate identification of patients who should be closely monitored because they
have a higher risk of recurrence. Adjuvant chemotherapy has previously been studied for its
potential  to  improve  survival  in  cholangiocarcinoma  (24,25).  A prospective  study of  this
approach  (ClinicalTrials.gov  identifier  NCT01313377)  is  currently  ongoing  and  aims  to
prevent and reduce the relapse rate of cholangiocarcinoma; however, as no recommendation
for adjuvant chemotherapy in this setting is currently available, it was used at the discretion of
the medical staff (oncologists and surgeons) involved in the care of the patients. This attitude
is neither rational nor suitable, and the determination of which cholangiocarcinoma patients
should  receive  adjuvant  chemotherapy  should  be  adjusted  based  on  factors  related  to
recurrence. In fact, for the high risk group of patients, it would seem beneficial to provide
adjuvant chemotherapy after curative PD. 
This study also provides important information regarding the types of recurrence of DCC. The
liver has been previously been reported as the most common site of disease spread, and this is
in agreement with the present results. Takao and al. were the first to demonstrate that liver
recurrence  after  R0  resection  occurred  significantly  more  frequently  than  other  types  of
recurrence (21 patients among 64, 33%, p<0.05)(26). 
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This  finding  has  since  been  widely  confirmed  by other  teams  (27,28).  In  addition,  liver
metastasis occurs at a higher rate  in resected DCC than in resected ampullary cancer (24% vs
10%, p=0.004), but the overall recurrence rates of these two cancers were similar, suggesting
the liver tropism of metastases from DCC such as the other biliary cancer (19).  To date, there
is no recommendation for the treatment of DCC recurrence, and in particularly, no relevant
strategy is currently available for the treatment of localized liver metastases. The results of the
present  study  perfectly  illustrate  this  fact,  as  patients  received  equal  benefits  from
chemotherapy,  combined  chemotherapy-radiotherapy  and  radiofrequency  ablation,  which
were  performed  in  85%,  1.8%  and  1.8%  of  patients,  respectively.  Aggressive  treatment
approaches for liver metastases after curative resection of DCC (radiofrequency ablation and
liver resection) have not been currently assessed or discussed in the literature.  In contrast,
aggressive treatment  approaches  have been examined for  their  possible  ability  to  prolong
survival in patients with liver metastases originating from cholangiocarcinomas with other
primary locations  than those of DCC  (29,30).  It  would be valuable  to  explore aggressive
treatment approaches for liver metastases originating from DCC in the near future to improve
the prognosis of this disease.
DCC has often been considered to have better prognosis than PDAC. However, studies that
have compared the long-term outcomes of patients with resected DCC and resected PDAC are
rare,  and  comparative  reports  with  relevant  matching  do  not  exist.  The  current  report
demonstrates for the first time that patients who underwent PD with curative intent for DCC
or PDAC had the same prognosis, with no significant differences in OS or DFS. Based on the
results of the current study, DCC may even have a worse prognosis than PDAC because most
cases of resected DCC did not receive adjuvant therapy unlike for cases of resected PDAC.
This  further  strengthens  the critical  need for  the discovery of new therapeutic  targets  for
adjuvant therapy in DCC.
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The present study showed that DCC could not be considered as small lesion as the median
size was 2.71 centimetres. This finding is consistent with previously reported studies (13,20)
and could be a potential explanation of the dismal prognosis observed. Indeed, a median size
higher than 2 centimetres was associated with worst OS and DFS in univariate analysis but
was not confirmed in multivariable analysis.
Of course, some possible weaknesses of the present study should be mentioned. First,  the
present results are based on a single centre series with a limited sample size and a long period
of recruitment. However, the low incidence of DCC partly explains the necessity of the long
duration of recruitment and the small sample size of this study, which was comparable to or
not higher than those of previous studies. Moreover,  the mean reported follow up (i.e. 28.8
months) is similar to previous study (9,22). Second, even though data were extracted from a
maintained prospective database, the statistical analysis was performed retrospectively. These
factors  may  have  generated  some  bias  and,  therefore,  the  results  of  this  study  must  be
confirmed by larger studies in the future. 
The present study generated new interesting sets of data regarding the oncological outcomes
of resected DCC. First, the characterization of recurrence, including risk factors that could
better define a high risk group was presented. Second, the true oncological outcomes of DCC
were compared to those of PDAC, which are two cancers that have the same prognosis. Both
increased  use  of  adjuvant  therapy  and  the  evaluation  of  aggressive  treatment  of  liver
metastases are necessary to improve the survival of patients with resected DCC.
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FIGURE LEGENDS
Figure 1. Patient selection flowchart
Figure 2. Characteristics of recurrences.
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Figure 3. Overall and disease-free survivals compared between patients who underwent
PD with curative intent for DCC (red line) and PDAC (black line). (A) Overall survival.
(B) Disease-free survival. a p=0.284, b p=0.43.
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Table 1. Univariable and multivariable analyses of clinicopathological factors that may
influence overall survival.
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Table 2. Univariable and multivariable analyses of clinicopathological factors that may
influence disease-free survival.
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Table 3. Patient characteristics of the two matched groups (DCC and PDAC). 
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